{"id":32256,"title":"Levodopa kinetic-dynamic test","title_html":"Levodopa kinetic-dynamic test","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.bbq8imzw","doi_status":2,"uri":"levodopa-kinetic-dynamic-test-bbq8imzw","type_id":1,"published_on":1583337964,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"created_on":1579853547,"categories":null,"creator":{"name":"Margherita Galletti","affiliation":null,"affiliations":[],"username":"margherita-galletti","link":"https:\/\/doi.org\/10.1371\/journal.pone.0229729","image":{"source":"\/img\/avatars\/014.png","placeholder":"\/img\/avatars\/014.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":"PLOS One","journal_name":"PLOS One","journal_link":"https:\/\/doi.org\/10.1371\/journal.pone.0229729","article_citation":"Ursino M,  Magosso E,  Lopane G,  Calandra-Buonaura G,  Cortelli P,  Contin M (2020) Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease. PLoS ONE  15(3): e0229729. doi: <a target=\"_blank\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0229729\">10.1371\/journal.pone.0229729<\/a> ","public":1,"has_versions":0,"link":"https:\/\/doi.org\/10.1371\/journal.pone.0229729","total_collections":0,"number_of_steps":6,"authors":[{"name":"Manuela Contin ","affiliation":"IRCCS- Istituto delle Scienze Neurologiche di Bologna- Dipartmento di Scienze Biomediche e Neuromotorie, Universit\u00e0 di Bologna, Bologna Italy","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"6E5520303E8011EA96F719C51E28DF2C","state_version_id":153,"steps":[{"id":872375,"guid":"425102503E8111EA96F719C51E28DF2C","previous_id":872380,"previous_guid":"844A6F503E8311EA96F719C51E28DF2C","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"5BAEA95566F64B55BCB57706552F9BFD","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"59F46528CE4846C7AC873AAAF1573985","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Blood samplings are drawn by an indwelling catheter before levodopa dosing, at 15-min intervals for the first 90 min, then half-hourly, up to 3 hours after dosing.\n<\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":872376,"guid":"425213C03E8111EA96F719C51E28DF2C","previous_id":872375,"previous_guid":"425102503E8111EA96F719C51E28DF2C","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"C5AEFF2003E249508E60D777EFB78538","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"5B727E1C00274D2DB098DB09E97652A9","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span>Blood specimens are transferred into heparinized tubes and immediately centrifuged at 1500<\/span><span style = \"font-style:italic;\">g <\/span><span>for 10 minutes at 4\u00b0C. Plasma samples are stored at \u221280\u00b0C until analysis (usually within 6 months).<\/span><\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":872377,"guid":"4252B0003E8111EA96F719C51E28DF2C","previous_id":872376,"previous_guid":"425213C03E8111EA96F719C51E28DF2C","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"D3C57FFBA1534C588DFCA10DD4D922D1","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"38D473B140A14761A1115A3BD8C4A71D","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">Levodopa plasma concentration measurements are performed by high-performance liquid chromatography (HPLC) with coulometric detection (Baruzzi, A., Contin, M., Albani, F., and Riva, R. (1986) Simple and rapid micromethod for the <\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr, 375:165-169).\n<\/div><\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":872378,"guid":"42539A603E8111EA96F719C51E28DF2C","previous_id":872377,"previous_guid":"4252B0003E8111EA96F719C51E28DF2C","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"3445F00C7B304212B0AB18B5CB631794","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"824DFE63CCAF4D9CB7C845AE6195C4AC","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Motor effects are tested by the alternate index finger tapping test (the number of times the patient could alternately tap two buttons 20 cm apart in 60 seconds with the most affected hand) up to 4 hours post-dosing, using a computerized touch screen system (mTapping, mHealth Technologies srl, Bologna, Italy).\n<\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":872379,"guid":"4254ABD03E8111EA96F719C51E28DF2C","previous_id":872378,"previous_guid":"42539A603E8111EA96F719C51E28DF2C","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"B28314D4993846518363DB90722028FB","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"1C43F6675C5740AF856CE68B13FD04D2","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">Possible levodopa induced dyskinesias are rated at the same times as motor responses by the Clinical Dyskinesia Rating Scale (CDRS) (Hagell P., Widner H. (1999) Clinical rating of dyskinesias in Parkinson\u2019s disease: use and <\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">reliability of a new rating scale. Mov Disord, 14: 448-455.).<\/div><\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":872380,"guid":"844A6F503E8311EA96F719C51E28DF2C","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E67DD54C32B847939F677F4E3673E024","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"5A81498FA9EA4FFEA028B4B01A8F1BFE","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Administration of a subacute test dose of levodopa (100 mg) plus benserazide (25 mg) or carbidopa (25 mg) under standardized conditions:<\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">- Fasting dosing<\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">- At least 12 hours of levodopa and possibly concomitant antiparkinsonian therapy wash-out<\/div><\/div><\/div>"}}],"cases":[],"data":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0}],"document":null,"materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\"> Levodopa oral test <\/span><\/div><div class = \"text-block\">Administration of a subacutest dose of levodopa (100 mg) plus benserazide (25 mg) or carbidopa (25 mg) under standardized conditions.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Levodopa kinetic\u2013dynamic monitoring<\/span><span><\/span><\/div><div class = \"text-block\">Measurements of plasma levodopa concentrations and clinical effects by objective motor tests (alternate finger tapping test). <\/div><\/div>","changed_on":1583337964}